Jennison Associates LLC Has $105.70 Million Position in Humana Inc. (NYSE:HUM)

Jennison Associates LLC lifted its position in Humana Inc. (NYSE:HUM - Free Report) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 333,725 shares of the insurance provider's stock after acquiring an additional 13,945 shares during the quarter. Jennison Associates LLC owned 0.28% of Humana worth $105,704,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HUM. Bessemer Group Inc. increased its position in Humana by 143.4% in the first quarter. Bessemer Group Inc. now owns 6,436 shares of the insurance provider's stock worth $2,230,000 after buying an additional 3,792 shares during the period. Lake Street Advisors Group LLC increased its holdings in shares of Humana by 17.1% in the 1st quarter. Lake Street Advisors Group LLC now owns 1,124 shares of the insurance provider's stock worth $391,000 after acquiring an additional 164 shares during the period. Pitcairn Co. boosted its stake in Humana by 23.0% during the 1st quarter. Pitcairn Co. now owns 1,672 shares of the insurance provider's stock valued at $580,000 after purchasing an additional 313 shares during the period. Advisors Asset Management Inc. grew its position in Humana by 4.5% in the 1st quarter. Advisors Asset Management Inc. now owns 5,370 shares of the insurance provider's stock worth $1,862,000 after purchasing an additional 230 shares during the last quarter. Finally, Capital International Inc. CA increased its stake in shares of Humana by 24.4% in the first quarter. Capital International Inc. CA now owns 12,809 shares of the insurance provider's stock valued at $4,441,000 after purchasing an additional 2,512 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of NYSE:HUM opened at $289.86 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average price of $277.86 and a 200 day moving average price of $331.03. The company has a market cap of $34.90 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 2.19 and a beta of 0.52. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $527.18.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion during the quarter, compared to analysts' expectations of $28.66 billion. Research analysts predict that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.22%. Humana's payout ratio is presently 31.36%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HUM shares. Wells Fargo & Company reduced their price objective on Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Jefferies Financial Group cut Humana from a "buy" rating to a "hold" rating and decreased their price target for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Barclays lifted their price objective on shares of Humana from $250.00 to $253.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. UBS Group decreased their target price on shares of Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a research report on Friday, October 4th. Finally, TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.